SMT201800593T1 - Inibitore per disturbi retinocoroidei - Google Patents

Inibitore per disturbi retinocoroidei

Info

Publication number
SMT201800593T1
SMT201800593T1 SM20180593T SMT201800593T SMT201800593T1 SM T201800593 T1 SMT201800593 T1 SM T201800593T1 SM 20180593 T SM20180593 T SM 20180593T SM T201800593 T SMT201800593 T SM T201800593T SM T201800593 T1 SMT201800593 T1 SM T201800593T1
Authority
SM
San Marino
Prior art keywords
retinochoroid
disorders
inhibitor
retinochoroid disorders
Prior art date
Application number
SM20180593T
Other languages
English (en)
Inventor
Kazuhiro Kimura
Original Assignee
Univ Yamaguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yamaguchi filed Critical Univ Yamaguchi
Publication of SMT201800593T1 publication Critical patent/SMT201800593T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J9/00—Feeding-bottles in general
    • A61J9/08—Protective covers for bottles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SM20180593T 2013-05-22 2014-05-21 Inibitore per disturbi retinocoroidei SMT201800593T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013107706 2013-05-22
EP14800477.3A EP3000466B1 (en) 2013-05-22 2014-05-21 Inhibitor for retinochoroidal disorders
PCT/JP2014/002667 WO2014188716A1 (ja) 2013-05-22 2014-05-21 網脈絡膜障害の抑制剤

Publications (1)

Publication Number Publication Date
SMT201800593T1 true SMT201800593T1 (it) 2019-02-28

Family

ID=51933283

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20180593T SMT201800593T1 (it) 2013-05-22 2014-05-21 Inibitore per disturbi retinocoroidei

Country Status (22)

Country Link
US (4) US10702502B2 (it)
EP (2) EP3000466B1 (it)
JP (2) JP6407145B2 (it)
KR (1) KR102303316B1 (it)
CN (1) CN105377258B (it)
AU (1) AU2014269762B2 (it)
BR (1) BR112015029114B1 (it)
CA (1) CA2913005C (it)
CY (1) CY1121036T1 (it)
DK (1) DK3000466T3 (it)
ES (2) ES2989991T3 (it)
HR (1) HRP20181876T1 (it)
LT (1) LT3000466T (it)
MX (1) MX362239B (it)
PL (1) PL3000466T3 (it)
PT (1) PT3000466T (it)
RS (1) RS58045B1 (it)
RU (1) RU2672057C2 (it)
SI (1) SI3000466T1 (it)
SM (1) SMT201800593T1 (it)
WO (1) WO2014188716A1 (it)
ZA (1) ZA201508940B (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2613776T3 (pl) 2010-09-01 2021-01-11 Thomas Jefferson University Kompozycja oraz sposób naprawy i regeneracji mięśni
CN109589324B (zh) 2012-11-08 2022-06-14 国立大学法人山口大学 角结膜病症的治疗剂
CN105377258B (zh) * 2013-05-22 2020-08-28 国立大学法人山口大学 视网膜脉络膜病症的抑制剂
ES2963348T3 (es) 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica
BR112019009929A2 (pt) 2016-11-16 2019-08-20 Clementia Pharmaceuticals Inc métodos para inibir a formação de um osteocondroma, para reduzir o tamanho de um osteocondroma, para desacelerar o crescimento de um osteocondroma e para reduzir hiperplasia de cartilagem

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015902A1 (en) 1993-01-11 1994-07-21 Ligand Pharmaceuticals Inc. Compounds having selectivity for retinoid x receptors
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
AU784377B2 (en) 2000-03-14 2006-03-23 Arthur V. Sampaio Compositions and methods for affecting osteogenesis
JP4118675B2 (ja) 2000-10-02 2008-07-16 エフ.ホフマン−ラ ロシュ アーゲー 気腫治療用新規レチノイド
PL209697B1 (pl) 2001-09-18 2011-10-31 Hoffmann La Roche Pochodne mocznika, środek farmaceutyczny i zastosowanie pochodnych mocznika
AU2002329276B2 (en) 2001-09-18 2008-04-24 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists I
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (ja) 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
AU2006227623B2 (en) * 2005-03-17 2011-10-20 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
EP1938815A1 (en) * 2005-09-27 2008-07-02 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by increase in vasopermeability
KR20070037188A (ko) 2005-09-30 2007-04-04 현대자동차주식회사 자동 변속기에서 유량 제어구조
WO2007113122A1 (en) 2006-03-31 2007-10-11 F. Hoffmann-La Roche Ag Process for preparing retinoid compounds
DK2026778T3 (en) 2006-05-16 2019-01-07 Io Therapeutics Llc RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS
CA2667706A1 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
EP2089023A2 (en) * 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with agonists of ppar-gamma
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
JP2009235031A (ja) 2008-03-28 2009-10-15 Nano Egg:Kk 角膜組織の再生促進剤
US8969350B2 (en) 2008-12-18 2015-03-03 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
EP2393915A4 (en) 2009-02-05 2012-12-26 Regenertech Pty Ltd PROCESS FOR THE PREPARATION OF PRECURSOR CELLS FROM DIFFERENTIATED CELLS
PL2613776T3 (pl) 2010-09-01 2021-01-11 Thomas Jefferson University Kompozycja oraz sposób naprawy i regeneracji mięśni
WO2012047674A2 (en) 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
US10485780B2 (en) 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US8772273B2 (en) 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
CN109589324B (zh) 2012-11-08 2022-06-14 国立大学法人山口大学 角结膜病症的治疗剂
CN105377258B (zh) 2013-05-22 2020-08-28 国立大学法人山口大学 视网膜脉络膜病症的抑制剂

Also Published As

Publication number Publication date
HRP20181876T1 (hr) 2019-03-08
DK3000466T3 (en) 2018-11-26
US20160120843A1 (en) 2016-05-05
US20240180873A1 (en) 2024-06-06
RS58045B1 (sr) 2019-02-28
WO2014188716A1 (ja) 2014-11-27
CY1121036T1 (el) 2019-12-11
LT3000466T (lt) 2019-02-11
NZ715245A (en) 2021-04-30
CN105377258B (zh) 2020-08-28
EP3446690A1 (en) 2019-02-27
ES2694831T3 (es) 2018-12-27
PT3000466T (pt) 2018-11-27
US12357613B2 (en) 2025-07-15
KR102303316B1 (ko) 2021-09-23
CA2913005A1 (en) 2014-11-27
CN105377258A (zh) 2016-03-02
US11730718B2 (en) 2023-08-22
AU2014269762A1 (en) 2016-01-07
HK1221909A1 (zh) 2017-06-16
JP6407145B2 (ja) 2018-10-17
EP3000466A4 (en) 2017-01-25
US20210121442A1 (en) 2021-04-29
CA2913005C (en) 2021-08-10
PL3000466T3 (pl) 2019-04-30
EP3000466B1 (en) 2018-08-15
BR112015029114A8 (pt) 2020-03-17
RU2015154741A (ru) 2017-06-28
EP3000466A1 (en) 2016-03-30
BR112015029114B1 (pt) 2020-11-24
JP2018115221A (ja) 2018-07-26
KR20160013075A (ko) 2016-02-03
US20260124176A1 (en) 2026-05-07
EP3446690C0 (en) 2024-09-11
MX362239B (es) 2019-01-09
JPWO2014188716A1 (ja) 2017-02-23
ES2989991T3 (es) 2024-11-28
RU2672057C2 (ru) 2018-11-09
AU2014269762B2 (en) 2019-09-12
SI3000466T1 (sl) 2019-02-28
BR112015029114A2 (pt) 2017-07-25
EP3446690B1 (en) 2024-09-11
ZA201508940B (en) 2017-11-29
MX2015016083A (es) 2016-03-21
US10702502B2 (en) 2020-07-07
JP6749962B2 (ja) 2020-09-02

Similar Documents

Publication Publication Date Title
LT3057586T (lt) Bromodomeno inhibitoriai
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
AR095266A1 (es) Inhibidores de bromodominios tetraciclicos
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
IL246002A0 (en) Novel methods
HRP20181129T1 (hr) Pirimidin inhibitori fgfr4
SMT201700363T1 (it) Inibitori di bromodominio cristallini
LT3060041T (lt) Prostaciklino junginiai
HRP20180460T1 (hr) Inhibitori syk
LT2841428T (lt) Dnr-pk inhibitoriai
DK2970336T3 (da) Tetrahydropyrrolothiazinforbindelser
ZA201506156B (en) Novel inhibitors
PT3055308T (pt) Resumo
HRP20171890T1 (hr) Supstituirani imidazopiridazini
DK2956698T5 (da) Bindestrimler
LT3563837T (lt) Terapija bakteriofagu
EP2988310A4 (en) CONVERTER
DK2946640T3 (da) Langmuir-probe
DE102013106534B8 (de) Chromatographiepipettenspitze
IL240904A0 (en) Azetidinyloxyphenylpyrrolidine compounds
ZA201508940B (en) Inhibitor for retinochoroidal disorders
HRP20180618T1 (hr) Spojevi fluorfenilpirazola
EP2958828A4 (de) Spender
DE112014001252A5 (de) Aufbissschiene
EP3060191C0 (en) A dispenser